Plus Therapeutics (PSTV)

• Market cap: $6.43M
• 1 day: 10.10%
• 5 days: -14.84%
• 1 month: -8.40%
• 3 months: -33.54%
• 6 months: -41.40%
• Year to date: -41.08%
• 1 year: -41.40%
• 5 years: -96.85%
• 10 years: -100.00%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Employees: 20

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.58% less ownership

Funds ownership: 11.96% [Q2] → 11.38% (-0.58%) [Q3]

2% less capital invested

Capital invested by funds: $1M [Q2] → $981K (-$21.4K) [Q3]

17% less funds holding

Funds holding: 12 [Q2] → 10 (-2) [Q3]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $8 634% upside
• Avg. target: $13.50 1,139% upside
• High target: $19 1,643% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Edward Woo 38% 1-year accuracy 28 / 73 met price target	1,643% upside $19	Buy Maintained	9 Dec 2024
HC Wainwright & Co. Sean Lee 60% 1-year accuracy 12 / 20 met price target	634% upside $8	Buy Reiterated	26 Nov 2024